Associated Genetic Biomarkers
Klotho beta (KLB) is a gene that encodes a protein that affects FGFR1 and FGFR4 binding to FGF21. Missense mutations, synonymous mutations, nonsense mutations, frameshift insertions, and frameshift deletions are observed in cancers such as skin cancer, colon cancer, and stomach cancer.
KLB status serves as an inclusion eligibility criteria in 1 clinical trial, of which 0 are open and 1 is closed. Of the trial that contains KLB status as an inclusion criterion, 1 is phase 1/phase 2 (0 open).
The most frequent alteration to serve as an inclusion eligibility criterion is KLB Expression .
Significance of KLB in Diseases
Malignant Solid Tumor +
KLB is an inclusion criterion in 1 clinical trial for malignant solid tumor, of which 0 are open and 1 is closed. Of the trial that contains KLB status and malignant solid tumor as inclusion criteria, 1 is phase 1/phase 2 (0 open) .
2. The UniProt Consortium. UniProt: a worldwide hub of protein knowledge. Nucleic Acids Research. 2019;47:D506-D515.
3. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 6. This dataset does not represent the totality of the genetic landscape; see paper for more information.